ReShape Lifesciences Inc - Asset Resilience Ratio
ReShape Lifesciences Inc (RSLS) has an Asset Resilience Ratio of 5.51% as of December 2018. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2006–2018)
This chart shows how ReShape Lifesciences Inc's Asset Resilience Ratio has changed over time. Check ReShape Lifesciences Inc (RSLS) strategic investment index to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down ReShape Lifesciences Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see ReShape Lifesciences Inc market cap and net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $2.55 Million | 5.51% |
| Total Liquid Assets | $2.55 Million | 5.51% |
Asset Resilience Insights
- Limited Liquidity: ReShape Lifesciences Inc maintains only 5.51% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
ReShape Lifesciences Inc Industry Peers by Asset Resilience Ratio
Compare ReShape Lifesciences Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
APT Medical Inc
SHG:688617 |
Medical Devices | 8.63% |
|
Medacta Group SA
SW:MOVE |
Medical Devices | 0.86% |
|
Jafron Biomedical Co Ltd
SHE:300529 |
Medical Devices | 39.15% |
|
Shanghai MicroPort EV MedTech Co. Ltd. A
SHG:688351 |
Medical Devices | 49.23% |
|
HOB Biotech Group Corp Ltd
SHG:688656 |
Medical Devices | 2.62% |
|
Shanghai General Healthy Information and Technology Co. Ltd.
SHG:605186 |
Medical Devices | 0.84% |
|
CareRay Digital Medical Technology Co Ltd
SHG:688607 |
Medical Devices | 16.21% |
|
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
SHE:002932 |
Medical Devices | 34.47% |
Annual Asset Resilience Ratio for ReShape Lifesciences Inc (2006–2018)
The table below shows the annual Asset Resilience Ratio data for ReShape Lifesciences Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2018-12-31 | 5.51% | $2.55 Million | $46.27 Million | -20.75pp |
| 2017-12-31 | 26.26% | $23.29 Million | $88.70 Million | -9.25pp |
| 2016-12-31 | 35.51% | $2.50 Million | $7.04 Million | -43.68pp |
| 2015-12-31 | 79.18% | $9.18 Million | $11.59 Million | -- |
| 2014-12-31 | 0.00% | $0.00 | $14.39 Million | -- |
| 2013-12-31 | 0.00% | $0.00 | $26.39 Million | -- |
| 2012-12-31 | 0.77% | $200.00K | $26.10 Million | -2.33pp |
| 2011-12-31 | 3.09% | $1.01 Million | $32.49 Million | -13.78pp |
| 2010-12-31 | 16.87% | $6.53 Million | $38.69 Million | -1.66pp |
| 2008-12-31 | 18.53% | $5.24 Million | $28.28 Million | +4.48pp |
| 2007-12-31 | 14.05% | $8.30 Million | $59.05 Million | -33.63pp |
| 2006-12-31 | 47.68% | $17.20 Million | $36.06 Million | -- |
About ReShape Lifesciences Inc
As of August 14, 2025, ReShape Lifesciences Inc. was acquired by Vyome Therapeutics Inc., in a reverse merger transaction. ReShape Lifesciences Inc. provides products and services that manage and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System to treat obesity and invasive surgical stapling… Read more